Silevertinib
AssetAlso called BDTX - 1535
Inhibits mutant EGFR signaling to suppress tumor growth.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- EGFR
- 2
- Indications
- 0
- Trials
- 1
- Developer
Named in the news on Nov 9, 2026. news.google.com
Indications
2Non-small cell lung cancer with EGFR non-classical mutations
Phase 2, news.google.com, Nov 9, 2026
Non-small cell lung cancer
Clinical, no phase, SEC filing, Mar 19, 2025
In the full profile
- Target and mechanism1
- Owner and partners1
- Evidence for its targets1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.